Cellular Immune Augmentation in Colon and Rectal Cancer
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
While new treatments for metastatic and recurrent colorectal cancer have become available
over the past several years, this disease remains incurable with a limited life expectancy
from the time of diagnosis. New strategies for treatment of disseminated colorectal cancer
are needed. Under this proposal, patients with advanced colorectal cancer will receive
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to stimulate endogenous dendritic
cells and enhance anti-tumor immune mechanisms. This will be combined with standard
chemotherapy and patients will be followed for response and overall survival. Detailed
correlative laboratory analysis will also be performed to define the extent of dendritic cell
and cellular immune system stimulation.